- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Nūhou
-
Nūhou
Lapaʻau ʻana i ka maʻi maʻi maʻi ʻāʻī hiki ʻole ke hoʻohana ʻia 2026: TIL hou a me nā mea hoʻokele Bispecific
Maʻiʻo The Paradigm Shift in Inoperable Lung Cancer Treatment Understanding Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: The Dual-Target Approach Comparative Analysis of Eme...
Lapaʻau ʻana i ka maʻi maʻi maʻi ʻāʻī hou 2026: Nā mea hou a me nā alakaʻi hou loa
Maʻiʻo ka hoʻomaopopo ʻana i ka maʻi maʻi maʻi ʻāʻī hou i ka makahiki 2026 Nā alakaʻi NCCN hou no ka hoʻomaʻamaʻa ʻana i ka maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi no nā hoʻolālā maʻi maʻi ʻāʻī hou no ka EGFR-Mutant Recu...
ʻO ka Lapaʻau ʻana i ka maʻi maʻi maʻi ʻāʻī o ka lolo 2026: nā kaʻina hana hou no ke ola lōʻihi
Maʻiʻo ka hoʻomaopopo ʻana i ka maʻi maʻi ʻaʻai ʻokoʻa i ka makahiki 2026 The Paradigm Shift: Mai ka ʻoki ʻoki koke ʻana i ka nānā ʻana i nā koho ʻokiʻoki liʻiliʻi liʻiliʻi no ka holomua ʻana o nā maʻi e emerging targeted T...
Papa 2A Lapaʻau ʻana i ka maʻi maʻi ʻāʻī 2026: ʻIkepili ELCC hou ma ka lāʻau lapaʻau Neo-Adjuvant
Maikaʻi ka hoʻomaopopo ʻana i ka pae 2A Non-Small Cell Lung Cancer 2026 ELCC Breakthroughs in Neo-Adjuvant Strategies Targeted Therapies for Driver-Mutated Stage 2A Lung Cancer Comparative Analysis of Trea...
ʻO ka Lapaʻau ʻana i ka maʻi maʻi maʻi ʻāʻī liʻiliʻi ma ka pae nui 2026: nā mea hou ʻo Iza-bren & Tarlatamab.
Maʻiʻo Ka Evolution of Extensive Stage Small Cell Lung Cancer Treatment Iza-bren: He Paradigm Shift in Bispecific ADC Therapy Tarlatamab and the Rise of T-Cell Engagers Safety and Tolerability in...
Lapaʻau ʻana i ka maʻi maʻi maʻi ʻāʻī hou 2026: Nā mea hou a me nā alakaʻi hou loa
Maʻiʻo ka hoʻomaopopo ʻana i ka maʻi maʻi maʻi ʻāʻī hou i ka makahiki 2026 Nā alakaʻi NCCN hou no ka hoʻomaʻamaʻa ʻana i ka maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi no nā hoʻolālā maʻi maʻi ʻāʻī hou no ka EGFR-Mutant Recu...
